Houston center Alperen Sengun left the Rockets’ loss to Dallas on Saturday night only 1:04 into play after spraining his ...

After winning Citrus Bowl MVP like his uncle Peyton did, Arch Manning jokes 'I don't want to have to play it twice' Medical ...

Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...

- Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory "The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated ...

Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in Gout Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory STOCKHOLM, Dec. 13, ...

Gout is a type of arthritis that is caused by the accumulation of uric acid in the body. Crystals of uric acid can form in a joint and this can lead to intense pain and inflammation. While, gout is ...

Scientists think snakes and lizards could help them find new ways to prevent painful kidney stones and gout in people. And it all owes to an evolutionary trick. Reptiles don't just pee; they ...

Colchicine, a cheap and widely used gout drug, may help prevent heart attacks and strokes in people with cardiovascular disease. Trials involving nearly 23,000 patients show meaningful reductions in ...

The MarketWatch News Department was not involved in the creation of this content. -- Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 ...

In gout, the drug choices for patients remain limited. The history of this field includes many molecules that fell short in the clinic or on the market for safety reasons. James Mackay knows firsthand ...

In this market, three things make fundraising easier for a biotech: a derisked asset touting a well-defined profile and an experienced team to guide the program’s development. Crystalys Therapeutics ...

Dotinurad is a next-generation, once daily oral, URAT1 inhibitor with potential for best-in-class safety and efficacy, as supported by extensive clinical data from Japan, China and other Asian markets ...